使用N-丁基-2-氰基丙烯酸酯行支气管动脉栓塞对化疗难治性肺门或纵隔肿瘤局部控制的有效性
单中心回顾性研究纳入42例2015–2018年化疗或放化疗难治性肺门或纵隔肿瘤患者,采用N-丁基-2-氰基丙烯酸酯(NBCA)行支气管动脉栓塞(BAE)。6个月内最佳局部反应完全缓解1例、部分缓解16例、疾病稳定24例、疾病进展1例,完全缓解/部分缓解率为40%(17/42);缓解组总生存显著优于稳定/进展组(p=0.006),3年生存率分别为45%(8/17)和0%(0/25)。作者认为BAE使用NBCA对缩小化疗或放化疗难治性肺门和/或纵隔肿瘤有潜在前景,并可能改善缓解患者的总生存。
要点
- 化疗或放化疗难治性肺门或纵隔肿瘤行NBCA-BAE后6个月内完全缓解/部分缓解率为40%(17/42)。
- 缓解组(完全缓解/部分缓解)总生存显著优于稳定/进展组(p=0.006)。
- 3年生存率缓解组45%(8/17)vs 稳定/进展组0%(0/25)。
核心结论
- BAE使用NBCA对缩小化疗或放化疗难治性肺门和/或纵隔肿瘤有潜在前景,并可能改善缓解患者的总生存。
研究设计与样本
- 单中心回顾性研究,纳入42例2015–2018年治疗的肺门或纵隔肿瘤患者(原发肿瘤5例、转移性37例;肉瘤22例、癌20例),所有患者既往化疗(n=37)或放化疗(n=5)后均显示肿瘤进展;采用NBCA行BAE以缩小肿瘤延长预期寿命,术后1、3、6个月用CT随访目标肿瘤。
诊断标准与关键数值
- 6个月内最佳局部反应:完全缓解1例、部分缓解16例、疾病稳定24例、疾病进展1例;完全缓解/部分缓解率为40%(17/42)。
临床应用与阅片要点
- 作者认为BAE使用NBCA对化疗或放化疗难治性肺门和/或纵隔肿瘤有潜在前景,并可能改善缓解患者的总生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To investigate local control and survival after bronchial artery embolization (BAE) using N-butyl-2-cyanoacrylate (NBCA) for pulmonary hilar or mediastinal tumors that are refractory to chemotherapy or chemoradiotherapy.
METHOD: This is a single center retrospective study involving 42 patients treated between 2015 and 2018 for pulmonary hilar or mediastinal tumors (primary tumors in 5 and metastatic ones in 37). Tumor histology was sarcoma in 22 and carcinoma in 20 patients. All patients had shown tumor progression regardless of previous chemotherapy (n = 37) or chemoradiotherapy (n = 5). Thirty-seven patients (88 %) had respiratory symptoms, such as cough, dyspnea, and hemoptysis. BAE was performed using NBCA to shrink tumors for extending life expectancy. Target tumors were followed with computed tomography at 1,3, and 6 months after BAE. Endpoints included the best tumor response within 6 months as well as overall survivals in patients with and without tumor responses.
RESULTS: Best local responses within 6 months were complete response (CR) in 1 patient, partial response (PR) in 16, stable disease (SD) in 24, and progressive disease (PD) in 1; the CR/PR rate was 40 % (17/42). Median follow-up period was 13 months (range:1-43). Overall survival in patients with CR/PR was significantly better than in those with SD/PD (p = 0.006); with 3-year survival rates of 45 % (8/17) and 0% (0/25), respectively.
CONCLUSIONS: BAE using NBCA has potential promise for shrinking hilar and/or mediastinal tumors that are refractory to chemotherapy or chemoradiotherapy, and may also improve overall survival in patients who respond.
引用
- Nomori H, Yamazaki I, Shiraishi A, et al. Effectiveness of bronchial arterial embolization using N-butyl-2-cyanoacrylate for local control of pulmonary hilar or mediastinal tumors that are refractory to chemotherapy. Eur J Radiol. 2020. PMID: 32858493. doi:10.1016/j.ejrad.2020.109160
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。